Investment risks in Mahamaya Lifesciences IPO include high dependency on a few large customers, lack of long-term supply agreements, raw material price volatility, regulatory approval uncertainties, seasonal demand affecting revenue, liquidity strains due to rising inventory and receivables, and competition from larger players.